topical intraoral ketoprofen gel — Competitive Intelligence Brief

topical intraoral ketoprofen gel (topical intraoral ketoprofen gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Oral Health.

phase 3 NSAID Oral Health Small molecule

Target snapshot

topical intraoral ketoprofen gel (topical intraoral ketoprofen gel) — Behar, Caren, M.D.. Topical intraoral ketoprofen gel works by reducing inflammation and pain in the mouth through the action of ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
topical intraoral ketoprofen gel TARGET	topical intraoral ketoprofen gel	Behar, Caren, M.D.	phase 3	NSAID
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Aleve	naproxen	Generic (originally Syntex)	marketed	NSAID	Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1	1976-01-01
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
Ibuprofen + Paracetamol	Ibuprofen + Paracetamol	Ullevaal University Hospital	marketed	Fixed-dose combination of NSAID and analgesic/antipyretic	COX-1/COX-2 (ibuprofen); central nervous system analgesic/antipyretic pathways (paracetamol)
Ketorolac + Ranibizumab	Ketorolac + Ranibizumab	Università degli Studi di Brescia	marketed	NSAID + anti-VEGF monoclonal antibody fragment	COX enzymes (ketorolac); VEGF-A (ranibizumab)
Aspirin (acetylsalicylic acid)	Aspirin (acetylsalicylic acid)	Swedish Medical Center	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID class)

1. Antibe Therapeutics Inc. · 3 drugs in this class
2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
3. Organon and Co · 2 drugs in this class
4. Apsen Farmaceutica S.A. · 2 drugs in this class
5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
6. Behar, Caren, M.D. · 2 drugs in this class
7. IDEA AG · 2 drugs in this class
8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
9. HALEON · 2 drugs in this class
10. Pfizer · 2 drugs in this class